NEW YORK, Jan. 2, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy market, today announced that the Company and its subsidiary, Progenitor Cell Therapy ("PCT"), will present at multiple conferences in January.
Biotech ShowcaseTM 2013
- Date: January 8, 2013, 4:15 PM PST
- Venue: Parc 55 Wyndham, San Francisco – Union Square, San Francisco, CA
- Speaker: Andrew L. Pecora, M.D., FACP, Chief Medical Officer and Director, NeoStem, will present on Amorcyte
Scale-Up and Manufacturing of Cell-Based Therapies II
- Date: January 22, 2013, 4:50 PM PST
- Venue: Hyatt Regency Mission Bay Spa and Marina, San Diego, CA
- Session Title: Cell Therapy Facility Design
- Speaker: Robert A. Preti, Ph.D., President and Chief Scientific Officer of PCT
Eighth International Conference on Cell Therapy for Cardiovascular Diseases (IC3D 2013)
- Date: January 24, 2013, 9:30 AM EST
- Venue: Vivian and Seymour Milstein Family Heart Center, New York City, NY
- Session Title: AMR-001 Phase 1 Outcome and PreSERVE Study Design: Autologous CD34+ Cells
- Speaker: Jonathan Sackner-Bernstein, M.D., FACC, Vice President of Clinical Development and Regulatory Affairs, NeoStem
Phacilitate's Cell & Gene Therapy Forum
- Venue: The Grand Hyatt, Washington, DC
-- Date: January 28, 2013, 10:40 AM EST
-- Session Title: Industry and payer perspectives - What are the current issues that might prevent a cell or gene therapy product candidate from being commercially viable, and how can they be addressed?
-- Panelist: Robert A. Preti, Ph.D., President and Chief Scientific Officer of PCT
-- Date: January 28, 2013, 1:05 PM EST
-- Session Title: How to optimize the financial and operational efficiency of an emerging cell therapy business?
-- Speaker: Sanjin Zvonic, Ph.D., Director, Technology & Business Development, PCT
-- Date: January 29, 2013, 3:05 PM EST
-- Session Title: Product characterization as a cornerstone of a commercially successful cell therapy product
-- Speaker: Timothy Fong, Ph.D., M.B.A., Vice President, Technology & Product Development, PCT
About NeoStem, Inc.
NeoStem, continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift occurring in medicine. We anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy industry. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, PCT, with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe that, with our expertise and research capabilities and collaborations, we will achieve our mission of becoming a premier cell therapy company.
Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert to create a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we are well positioned to succeed.
For more information, please visit www.neostem.com.
Forward-Looking Statements for NeoStem, Inc.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its contract development and manufacturing business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors, including but not limited to matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.